Suppr超能文献

哮喘中的生物制剂:实现临床缓解的潜力。

Biologics in Asthma: Potential to Achieve Clinical Remission.

机构信息

Division of Allergy and Immunology, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.

Division of Allergy and Immunology, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.

出版信息

Immunol Allergy Clin North Am. 2024 Nov;44(4):725-736. doi: 10.1016/j.iac.2024.08.004. Epub 2024 Sep 6.

Abstract

Establishing a universal definition for asthma remission has the potential to improve asthma outcomes and advance research. However, there is still no consensus definition despite broad multidisciplinary efforts to achieve this goal. This study explores the evolving concept of asthma remission, emphasizing the potential of biologics to achieve this state. We will discuss various proposed definitions of asthma remission, international guidelines, and studies evaluating the effectiveness of biologics at achieving clinical remission. We highlight the need for a consensus definition of asthma remission to standardize treatment goals and improve patient outcomes.

摘要

为哮喘缓解建立一个通用的定义有可能改善哮喘的结局并推动研究的进展。然而,尽管进行了广泛的多学科努力来实现这一目标,但仍然没有达成共识的定义。本研究探讨了哮喘缓解的不断发展的概念,强调了生物制剂实现这一状态的潜力。我们将讨论各种提出的哮喘缓解定义、国际指南以及评估生物制剂在实现临床缓解方面的有效性的研究。我们强调需要达成一个哮喘缓解的共识定义,以标准化治疗目标并改善患者的结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验